All News

Found 834 articles

• Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression

  5/18/2022

  Homology Medicines, Inc., a genetic medicines company, unveiled the mechanism of action and optimization of HMI-103, the nuclease-free gene editing candidate currently in a Phase 1 trial for phenylketonuria.

• Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details

  5/18/2022

  Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT.

• Cara Therapeutics to Present at Upcoming Investor Conferences

  5/17/2022

  Cara Therapeutics, Inc. today announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences: H.C. Wainwright Global Investment Conference Wednesday, May 25, 2022, at 10:30 a.m. ET.

• Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights

  5/16/2022

  Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments.

• Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting

  5/16/2022

  Affinia Therapeutics today announced results from preclinical studies presented in an oral session at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

• Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results

  5/5/2022

  Vir Biotechnology, Inc. provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

• Cara Therapeutics to Present at May 2022 Investor Conferences

  5/3/2022

  Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences in May.

• Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting

  5/2/2022

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the first presentation detailing the optimization and mechanism of action of its HMI-103 nuclease-free gene editing candidate for phenylketonuria (PKU) will take place during the American Society for Gene & Cell Therapy (ASGCT) 25th Annual Meeting May 16-19, 2022.

• Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

  4/29/2022

  Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 9, 2022, at 4:30 p.m. ET to report first quarter 2022 financial results and provide a corporate update.

• Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

  4/28/2022

  Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that the European Commission has granted marketing authorization to Kapruvia® for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.

• Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day

  4/27/2022

  Vir Biotechnology, Inc. announced that the Company will review its robust hepatitis portfolio, including initial data from the first cohort of the MARCH trial evaluating VIR-2218 in combination with VIR-3434, as well as a new program aimed at chronic hepatitis D. Details will be discussed at 12:00 pm ET / 9:00 am PT during Vir’s virtual Hepatitis Portfolio R&D Day.

• ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone

  4/27/2022

  ContraFect Corporation announces presentation data showing DLA CF-370 is highly efficacious in a rabbit pneumonia model of a particularly hard-to-treat, extensively-drug-resistant strain of Pseudomonas aeruginosa, and also has the ability to both avoid antimicrobial resistance and suppress antibiotic resistance to commonly-used antibiotics in vitro.

• Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President

  4/21/2022

  Homology Medicines, Inc., a genetic medicines company, announced that Albert Seymour, Ph.D., Chief Scientific Officer, has been promoted to President of Homology.

• Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022

  4/21/2022

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022.

• Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day

  4/13/2022

  Vir Biotechnology, Inc. announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community on Wednesday, April 27, from 12:00 – 2:00 p.m. ET.

• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.

• Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/5/2022

  Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022, at 1:30 p.m. ET.

• 

  Clinical Catch-Up: Adagio to Seek COVID-19 EUA, CytoDyn's Bad Week

  4/4/2022

  It was a particularly busy week for clinical trial announcements. Let's take a look.

• Enteris BioPharma Highlighted as Game Changer in Drug Development & Delivery Special Feature on Innovative Technologies for Improving Drug Solubility and Bioavailability

  4/4/2022

  Enteris BioPharma, Inc. announced that CEO, Rajiv Khosla, Ph.D., was featured in Drug Development and Delivery discussing the ability of Enteris' Peptelligence® and ProPerma® technologies to overcome the permeability and solubility issues that prevent the oral delivery of many "beyond the rule of 5" compounds, including peptides, peptidomimetics, and intermediate-sized small molecule compounds.

• Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

  4/4/2022

  Cara Therapeutics, Inc. KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing hemodialysis will be presented in a poster at the National Kidney Foundation Spring Clinical Meetings 2022 (SCM22), to be held April 6-10, 2022, in Boston, MA.